Document:

Exhibit 10.46

 

Restricted
stock unit AGREEMENT

EKSO BIONICS HOLDINGS, INC.

 

THIS restricted
stock unit AGREEMENT (this “Agreement”) is entered into as of the ___ day of _____, 201__ (the “Grant
Date”)

 

BETWEEN:

 

EKSO BIONICS HOLDINGS, INC., a
company incorporated pursuant to the laws of the State of Nevada (the “Company”),

 

AND:

 

[INSERT
NAME], of [INSERT CITY], [INSERT STATE] (the “Grantee”).

 

WHEREAS:

 

A.                
The Board of Directors of the Company (the “Board”) has approved and adopted the Ekso Bionics Holdings,
Inc. 2014 Equity Incentive Plan (the “Plan”), pursuant to which awards of Restricted Stock Units may be granted;
and

 

B.       The Compensation
Committee of the Board has determined that it is in the best interests of the Company and its shareholders to grant the award of
Restricted Stock Units provided for herein (the “Award”).

 

NOW, THEREFORE, the parties hereto, intending to be legally
bound, agree as follows:

 

1.          Grant
of Restricted Stock Units.

 

1.1           Pursuant to Section 9 of the Plan, the Company hereby issues to the Grantee on the Grant Date the Award consisting of, in
the aggregate, [NUMBER] Restricted Stock Units (the “Restricted Stock Units”). Each Restricted Stock Unit represents
the right to receive one share of Common Stock, subject to the terms and conditions set forth in this Agreement and the Plan. Capitalized
terms that are used but not defined herein have the meaning ascribed to them in the Plan.

 

1.2           The Restricted Stock Units shall be credited to a separate account maintained for the Grantee on the books and records of
the Company (the “Account”). All amounts credited to the Account shall continue for all purposes to be part
of the general assets of the Company.

 

2.          Consideration.
The grant of the Restricted Stock Units is made in consideration of the services to be rendered by the Grantee to the Company.

 

3.          Vesting.

 

3.1           Except as otherwise provided herein, provided that the Grantee remains in Continuous Service (as defined below) through
the applicable vesting date described below, the Restricted Stock Units will vest in accordance with the following schedule (the
period during which restrictions apply, the “Restricted Period”):

 

     

     

    

 

	Vesting Date	Number of Restricted Stock Units That Vest
	[VESTING DATE]	[NUMBER OR PERCENTAGE OF UNITS THAT VEST ON THE VESTING DATE]
	[VESTING DATE]	[NUMBER OR PERCENTAGE OF UNITS THAT VEST ON THE VESTING DATE]

Once vested, the Restricted Stock
Units become “Vested Units.”

 

3.2           The foregoing vesting schedule notwithstanding, if the Grantee's Continuous Service terminates for any reason at any time
before all of his or her Restricted Stock Units have vested, the Grantee's unvested Restricted Stock Units shall be automatically
forfeited upon such termination of Continuous Service and neither the Company nor any Affiliate shall have any further obligations
to the Grantee under this Agreement; provided, however, that in the event that the Grantee is party to a written employment agreement
with the Company pursuant to which service-based vesting requirements applicable to equity awards are excused, in whole or in part,
upon the occurrence of a Change in Control, then the foregoing vesting schedule shall be deemed to incorporate by reference such
provisions. For purposes of this Agreement, the term “Continuous Service” means that the Grantee’s service
with the Company or an Affiliate, whether as an Employee, Consultant or Director, is not interrupted or terminated. The Grantee’s
Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Grantee renders
service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Grantee renders
such service, provided that there is no interruption or termination of the Grantee’s Continuous Service; provided
further that if this Agreement is subject to Section 409A of the Code, this sentence shall only be given effect to the
extent consistent with Section 409A of the Code. The Administrator or its delegate, in its sole discretion, may determine whether
Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave,
military leave or any other personal or family leave of absence.

 

3.3           The foregoing vesting schedule notwithstanding, if a Change in Control occurs and the Grantee's Continuous Service is terminated
by the Company or an Affiliate without Cause or by the Grantee for Good Reason, and the Grantee's date of termination occurs within
twelve (12) months following the Change in Control, all unvested Restricted Stock Units shall automatically become 100% vested
on the Grantee's date of termination.

 

For the purposes of this Agreement,
the following terms shall be defined as is below, unless otherwise set forth in an applicable employment agreement between the
Company (or one of its Affiliates) and the Grantee:

 

“Cause”
for termination by the Company of the Grantee’s Continuous Service shall arise when termination results from (A) the willful
and continued failure or refusal of Grantee to satisfactorily perform the duties reasonably required of him or her as an Employee,
Consultant or Director of the Company, which failure or refusal continues for more than thirty (30) days after notice given to
Grantee, such notice to set forth in reasonable detail the nature of such failure or refusal; (B) Grantee’s conviction of,
or plea of nolo contendere to, (i) any felony or (ii) a crime involving dishonesty or misappropriation or which could reflect negatively
upon the Company or otherwise impair or impede its operations; (C) Grantee’s misconduct,
gross negligence, act of dishonesty (including, without limitation, theft or embezzlement), violence, threat of violence or any
activity that could result in any material violation of federal securities laws, in each case, that is injurious to the Company
or any of its Affiliates; (D) Grantee’s material breach of a written policy of the Company or the rules of any governmental
or regulatory body applicable to the Company; or (E) other willful misconduct by Grantee which is materially injurious to the financial
condition or business reputation of the Company or any of its Affiliates.

 

    2

     

    

 

“Good Reason”
shall mean the Grantee’s termination of Continuous Service within ninety (90) days following any of the following events
(without the Grantee’s express written consent): (A) a material reduction by the Company in the Grantee’s then applicable
base salary or other compensation, unless said reduction is pari passu with other employees of the Company; (B) a material reduction
in the Grantee’s job responsibilities; or (C) a geographical relocation of the Grantee more than fifty (50) miles from the
current location of the Grantee’s place of employment. Notwithstanding the foregoing, a termination of a Grantee for Good
Reason shall not have occurred unless (i) the Grantee gives written notice to the Company (or its Affiliate) within thirty
(30) days after the Grantee first becomes aware of the occurrence of the circumstances constituting Good Reason, and the Company
(or its Affiliate) has failed within thirty (30) days after receipt of such notice to cure the circumstances constituting
Good Reason.

 

4.          Restrictions.
Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period and until such time as the Restricted
Stock Units are settled in accordance with Section 6, the Restricted Stock Units or the rights relating thereto may not be assigned,
alienated, pledged, attached, sold or otherwise transferred or encumbered by the Grantee. Any attempt to assign, alienate, pledge,
attach, sell or otherwise transfer or encumber the Restricted Stock Units or the rights relating thereto shall be wholly ineffective
and, if any such attempt is made, the Restricted Stock Units will be forfeited by the Grantee and all of the Grantee's rights to
such units shall immediately terminate without any payment or consideration by the Company.

 

5.          Rights
as Shareholder.

 

5.1              
The Grantee shall not have any rights of a shareholder with respect to the shares of Common Stock underlying the Restricted
Stock Units unless and until the Restricted Stock Units vest and are settled by the issuance of such shares of Common Stock.

 

5.2              
Upon and following the settlement of the Restricted Stock Units, the Grantee shall be the record owner of the shares of
Common Stock underlying the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record
owner shall be entitled to all rights of a shareholder of the Company (including voting rights).

 

6.          Settlement of Restricted
Stock Units. Subject to Section 13 hereof, as soon as administratively practical following each vesting date,
and in any event no later than March 15 of the calendar year following the calendar year in which such vesting date occurs, the
Company shall (a) issue and deliver to the Grantee the number of shares of Common Stock equal to the number of Vested Units; and
(b) enter the Grantee's name on the books of the Company as the shareholder of record with respect to the shares of Common Stock
delivered to the Grantee.

 

7.          Adjustments.
In the case of any stock split, stock dividend or like change in the nature of shares of Stock covered by this Agreement, the Restricted
Stock Units shall be adjusted or terminated in any manner as contemplated by Section 14(a) of the Plan.

 

8.          Resale restrictions may apply. Any resale of the shares of Common Stock received upon settlement of Vested Units
will be subject to resale restrictions contained in the securities legislation applicable to the Grantee. The Grantee acknowledges
and agrees that the Grantee is solely responsible (and the Company is not in any way responsible) for compliance with applicable
resale restrictions.

 

    3

     

    

 

9.          Subject to 2014 Plan. The terms of the Restricted Stock Units are subject to the provisions of the 2014 Plan, as
the same may from time to time be amended, and any inconsistencies between this Agreement and the 2014 Plan, as the same may be
from time to time amended, shall be governed by the provisions of the 2014 Plan, a copy of which has been delivered to the Grantee,
and which is available for inspection at the principal offices of the Company.

 

10.        Professional Advice. The acceptance of the Restricted Stock Units and the sale of Common Stock issued upon settlement
of the Restricted Stock Units may have consequences under foreign, federal and state tax (including social security contributions)
and securities laws which may vary depending upon the individual circumstances of the Grantee. Accordingly, the Grantee acknowledges
that he or she has been advised to consult his or her personal legal and tax advisor in connection with this Agreement and his
or her dealings with respect to Restricted Stock Units. Without limiting other matters to be considered with the assistance of
the Grantee’s professional advisors, the Grantee should consider: (a) the foreign, federal, state and local tax consequences
(including social security contributions) of this Agreement, including without limitation the grant of Restricted Stock Units hereunder;
(b) the merits and risks of an investment in the underlying shares of Common Stock; and (c) any resale restrictions that might
apply under applicable securities laws.

 

11.        No Right to Continued Service.
Neither the Plan nor this Agreement shall confer upon the Grantee any right to be retained in any position, as an Employee, Consultant
or Director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company
to terminate the Grantee's Continuous Service at any time, with or without Cause.

 

12.        Entire Agreement. This Agreement is the only agreement between the Grantee and the Company with respect to the Restricted
Stock Units, and this Agreement and the 2014 Plan supersede all prior and contemporaneous oral and written statements and representations
and contain the entire agreement between the parties with respect to the Restricted Stock Units.

 

13.        Tax
Liability and Withholding.

 

13.1         The Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any cash compensation,
including wages, paid to the Grantee by the Company or one of its Affiliates, the amount of any required withholding taxes in respect
of the Restricted Stock Units and to take all such other action as the Administrator deems necessary to satisfy all obligations
for the payment of such withholding taxes. The Administrator, in its sole discretion and pursuant to such procedures as it may
specify from time to time, may permit the Grantee to satisfy any federal, state or local tax withholding obligation, in whole or
in party by any of the following means:

 

(a)       paying cash;

 

(b)       electing to have the Company withhold otherwise deliverable shares of Common Stock having a Fair Market Value equal to the
amount required to be withheld, provided, however, that no shares of Common Stock shall be withheld with a value exceeding the
maximum amount of tax required to be withheld by law;

 

(c)       delivering to the Company already-owned shares of Common Stock having a Fair Market Value equal to the amount required to
be withheld;

 

    4

     

    

 

(d)       selling a sufficient number of shares of Common Stock otherwise deliverable to the Grantee through such means as the Administrator
may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld; or

 

(e)       any combination of the foregoing.

 

13.2         Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other
tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains
the Grantee's responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related
Items in connection with the grant, vesting or settlement of the Restricted Stock Units or the subsequent sale of any shares; and
(b) does not commit to structure the Restricted Stock Units to reduce or eliminate the Grantee's liability for Tax-Related Items.

 

14.        Compliance
with Law. The issuance and transfer of shares of Common Stock shall be subject to compliance by the Company and the
Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock
exchange on which the Company's shares of Common Stock may be listed. No shares of Common Stock shall be issued or transferred
unless and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with
to the satisfaction of the Company and its counsel.

 

15.        Consent to Transfer of Personal Data. In administering the Plan, or to comply
with applicable legal, regulatory, tax, or accounting requirements, it may be necessary for the Company to transfer certain Grantee
data to an affiliate or to its outside service providers or governmental agencies. By accepting the Restricted Stock Unit, the
Grantee consents, to the fullest extent permitted by law, to the use and transfer, electronically or otherwise, of the Grantee’s
personal data to such entities for such purposes.

 

16.        Notices.
Any notice required or permitted to be made or given hereunder shall be mailed or delivered personally to the addresses set forth
below, or as changed from time to time by written notice to the other:

 

		The Company:	Ekso Bionics Holdings, Inc.
	 	 	1414
Harbour Way South, Suite 1201

Richmond, California 94804

Attention: Chief Financial Officer
 
	 	 	 
	 	The Grantee:	[INSERT NAME]
	 	 	[INSERT ADDRESS]

  

17.        Interpretation.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Administrator
for review. The resolution of such dispute by the Administrator shall be final and binding on the Grantee and the Company.

 

18.        Successors
and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this
Agreement will be binding upon the Grantee and the Grantee's beneficiaries, executors, administrators and the person(s) to whom
the Restricted Stock Units may be transferred by will or the laws of descent or distribution.

 

    5

     

    

 

19.        Severability.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and
enforceable to the extent permitted by law.

 

20.        Discretionary
Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in
its discretion. The grant of the Restricted Stock Units in this Agreement does not create any contractual right or other right
to receive any Restricted Stock Units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the
Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions
of the Grantee's employment with the Company.

 

21.        Amendment.
The Administrator has the right to amend, alter, suspend, discontinue or cancel the Restricted Stock Units, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Grantee's material rights under this Agreement without the Grantee's
consent.

 

22.        Section
409A. This Award is intended to be a short-term deferral exempt from Section 409A of the Code and shall be interpreted
consistent with this intention. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits
provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion
of any taxes, penalties, interest or other expenses that may be incurred by the Grantee on account of non-compliance with Section
409A of the Code.

 

23.        No
Impact on Other Benefits. The value of the Grantee's Restricted Stock Units is not part of his or her normal or expected
compensation for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.

 

24.        Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

 

25.        Acceptance.
The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms
and provisions thereof, and accepts the Restricted Stock Units subject to all of the terms and conditions of the Plan and this
Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the vesting or settlement of the Restricted
Stock Units or disposition of the underlying shares and that the Grantee has been advised to consult a tax advisor prior to such
vesting, settlement or disposition.

 

[signature page
follows]

 

    6

     

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the date first above written.

 

	 	Ekso Bionics Holdings, Inc.
	 	 
	 	 
	 	
        

        By: ____________________________________

        Name:

        Title:

	 	 
	 	 
	 	
        GRANTEE:

	 	 
	 	 
	 	
        

        Signature: _______________________________

         

        Name (please type or print):__________________

	 	 

 

    7Exhibit 10.47

 

Warrant
Repurchase and amendment AGREEMENT

 

This Warrant
Repurchase and amendment Agreement (this “Agreement”) is made this 4th day of August, 2017,
between Ekso Bionics Holdings, Inc., a Nevada corporation (the “Company”) and the warrant holder identified
on the signature page hereto (“Holder”). Capitalized terms used in this Agreement but not otherwise defined
herein shall have the meanings ascribed to such terms in the Securities Purchase Agreement dated April 2, 2017 between the Company
and the purchasers party thereto (the “Purchase Agreement”).

 

RECITALS:

 

WHEREAS, the Company and Holder are parties
to the Purchase, pursuant to which Holder received that Common Stock Purchase Warrant to purchase the number of shares of Common
Stock set forth on the signature page hereto (the “Warrant”);

 

WHEREAS, the Company intends to undertake
an offering to each of its shareholders and certain warrant holder of its common stock, par value $0.001 per share (“Common
Stock”), of record as of the close of business on August 10, 2017, of non-transferable rights (the “Rights”)
to subscribe for and purchase such number of additional shares of Common Stock (the “New Shares”) at a subscription
price per share of $1.00 (the “Per Share Subscription Price”) constituting an aggregate offering amount of $34.0
million (such offering, the “Rights Offering”); and

 

WHEREAS, contingent on Holder’s participation
in the Rights Offering on the terms set forth in this Agreement, the Company wishes to repurchase from Holder, and Holder wishes
to sell to the Company, the Warrant at a price of $1.23 per share of Common Stock issuable upon exercise of the Warrant (the “Per
Share Repurchase Price”);

 

NOW, THEREFORE, in consideration of the
mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties hereto each agree as follows:

 

1.       Purchase
and Sale of the Warrant. Subject to the terms and conditions stated herein, on the Closing Date (as defined below), Holder
agrees to sell, assign, transfer and deliver to the Company, and the Company agrees to purchase and redeem from Holder, free and
clear of all Encumbrances (as defined below), the Warrant in consideration for an amount equal to the Per Share Repurchase Price
multiplied by the number of Warrant Shares into which the Warrant is currently exercisable, as set forth on the signature page
hereto (the “Aggregate Repurchase Price”).

 

 2.       Amendments to the Purchase Agreement.

 

(a)       Section
4.12 of the Purchase Agreement is hereby deleted in its entirety and the following inserted in lieu thereof: “4.12. [RESERVED].”

 

(b)Section 1.1 of
the Purchase Agreement by inserting the following at the end of the definition of “Exempt Issuances”: 

 

“and (d) Common Stock Equivalents or rights
to purchase stock, warrants, securities or other property pro rata to all record holders of any class of shares of Common Stock.”

 

    	 

     

    

 

3.       Closing;
Closing Deliveries.

 

(a)       The
closing of the transactions contemplated by this Agreement (the “Closing”) shall take place at 10:00 a.m. Eastern
Time on the later of (i) three Trading Days after the Rights Offering Expiration Date (as defined below) and (ii) one Trading Day
following the date that all of the conditions to the Closing set forth in Section 4 have been satisfied or waived (other
than those conditions that by their nature are to be satisfied at the Closing) (or on such other date thereafter as the parties
hereto mutually agree) (the date upon which the Closing actually occurs, the “Closing Date”).

 

(b)       At
the Closing, Holder shall deliver the Warrant to the Company, and the Company shall deliver to Holder an amount equal to the Aggregate
Repurchase Price. Notwithstanding the foregoing, each of the Company and Holder agree that in lieu of the Company delivering the
Aggregate Repurchase Price to Holder, the Company may instead deduct such amount from the amount to be paid by Holder to the Company
in consideration for Holder’s exercise of Rights in the Rights Offering. In such event, the Company will deliver to VStock
Transfer, LLC (the “Subscription Agent”) an instruction letter setting forth the aggregate amount paid directly
to the Company in connection with the Rights Offering and instructing the Subscription Agent to issue the number of New Shares
in the Rights Offering equal to the lesser of (i) the Aggregate Repurchase Price divided by the Per Share Subscription Price or
(ii) Holder’s basic subscription right, plus any oversubscription right to which Holder is entitled under the terms of the
Rights Offering. For the avoidance of doubt, any New Shares issued in the Rights Offering to the Holder shall be delivered in such
manner and at such time as all other New Shares are delivered in the Rights Offering. In the event that the Aggregate Repurchase
Price exceeds an amount equal to the number of New Shares issuable to Holder pursuant to the Rights Offering multiplied by the
Per Share Subscription Price, the Company shall notify the Holder of such event and the amount of cash payments that will be made
on or prior to the Closing and shall pay the amount of any such excess in cash by wire transfer of immediately available funds
on the Closing Date. Notwithstanding anything to the contrary contained herein, the Holder may elect not to deliver the Warrant
to the Company for repurchase by delivery of a written notice (which may be by facsimile or email delivery) to the Company on or
prior to the Closing so electing. If a Holder makes such election and the Company is otherwise ready, willing and able to honor
its obligations hereunder, notwithstanding anything to the contrary set forth herein, the releases set forth in Section 7 hereof
shall become effective upon delivery of such notice. For the avoidance of doubt, the Holder’s election not to deliver the Warrant
to the Company for repurchase shall not impact the Holder’s right to otherwise participate in the Rights Offering.

 

4.       Closing
Conditions.

 

(a)       The
obligations of the Company to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver
by the Company in writing of following conditions:

 

i.       on
or prior to the date on which the subscription period under the Rights Offering expires (the “Rights Offering Expiration
Date”), Holder shall have delivered a properly completed and duly executed rights certificate to the Subscription Agent
electing to exercise not less than Holder’s basic subscription right pursuant to the Rights Offering in full, which rights
certificate shall not have been withdrawn or revoked as of the Rights Offering Expiration Date;

 

ii.       the
Company will not have cancelled the Rights Offering;

 

iii.       the
representations and warranties of Holder set forth below shall be true and correct as of the Closing Date; and

 

    	 	2	 

     

    

 

iv.       this
Agreement or substantially identical agreements (collectively, the “Repurchase Agreements”) shall have been
executed by the Purchasers (as defined in the Purchase Agreement) which purchased in the aggregate at least 90% in interest of
the shares sold pursuant to the Purchase Agreement based on the Initial Subscription Amounts (as defined in the Purchase Agreement)
under the Purchase Agreement and all such Purchasers shall have delivered either (x) a properly completed and duly executed rights
certificate to the Subscription Agent electing to exercise not less than each such Purchaser’s basic subscription right pursuant
to the Rights Offering, which rights certificate shall not have been withdrawn or revoked as of the Rights Offering Expiration
Date or (y) releases substantially similar to those set forth in Section 7 hereof, which shall have become effective with respect
to the Company and each such Purchaser.

 

(b)       The
obligations of Holder to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver by
Holder in writing of following conditions:

 

i.       the
Company will not have cancelled the Rights Offering; and

 

ii.       the
representations and warranties of the Company set forth below shall be true and correct as of the Closing Date.

 

5.       Representations
and Warranties of Holder. Holder hereby represents and warrants to the Company as of the date hereof and as of the Closing
Date:

 

(a)       Ownership.
All of the Warrants are owned of record and beneficially by Holder and Holder has good and marketable title to the Warrants, free
and clear of any security interest, claims, liens, pledges, options, encumbrances, charges, agreements, voting trusts, proxies
or other arrangements or restrictions whatsoever (collectively, “Encumbrances”), except for such legend and
related transfer restrictions as are required under the Securities Act, and the restrictions set forth in the Purchase Agreement.
On the Closing Date, Holder shall deliver to the Company good and marketable title to the Warrants, free and clear of any Encumbrances.

 

(b)       Authorization;
Enforcement. The execution and delivery of this Agreement and performance by such Purchaser of the transactions contemplated
by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability company or similar action,
as applicable, on the part of such Purchaser. This Agreement has been duly executed by such Purchaser, and when delivered by such
Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

6.       Representations
and Warranties of the Company. The Company hereby represents and warrants to Holder as of the date hereof and as of the Closing
Date:

 

(a)       Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the Company
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders in
connection herewith other than the filing with the Commission of a prospectus supplement complying with Rule 424(b) of the Securities
Act, the notice and/or application(s) to each applicable Trading Market, and any filings that may be required under applicable
state securities laws or blue sky laws. This Agreement has been duly executed by the Company and, when delivered in accordance
with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

    	 	3	 

     

    

 

(b)       Warrants.
The Company hereby represents and warrants that the aggregate number of shares of Common Stock underlying Warrants that are eligible
for repurchase by the Company pursuant to the Repurchase Agreement is 1,866,178 shares.

 

7.       Releases.

 

(a)       Holder
Release. In consideration of the Company’s execution of this Agreement, and effective upon the Closing Date, the Holder,
for itself and for its officers, directors, agents, employees, attorneys, business units, divisions, affiliates, direct or indirect
parent corporations, subsidiaries, predecessors in interest, administrators, agents, successors and assigns (collectively, the
“Holder Releasors”), hereby remise, release and forever discharge, the Company and its officers, directors,
agents, employees, attorneys, business units, divisions, affiliates, direct or indirect parent corporations, subsidiaries, predecessors
in interest, administrators, agents successors and assigns (collectively, the “Company Releasees”) of and from
all manner of claims, charges, complaints, demands, actions, causes of action, suits, rights, appeals and rights of appeal, debts,
dues, sums of money, costs, losses, accounts, reckonings, covenants, contracts, controversies, agreements, promises, leases, doings,
omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs) of every kind,
nature and description whatsoever, whether known or unknown, existing or contingent, ascertained or unascertained, asserted or
unasserted, suspected or unsuspected, in law, equity or mixed, whether for compensatory, multiple or punitive damages or other
relief, real or alleged (collectively, “Claims”), that each Holder Releasor ever had, now has or hereafter may
have against the Company and/or the Company Releasees based upon any alleged conduct, action, or omission from the beginning of
the world to the Closing Date arising out of, concerning or relating, directly or indirectly, to the Purchase Agreement or to the
purchase, sale, or issuance of the Shares or Warrants and related agreements or actions. The Claims released by the Holder Releasors
pursuant to this Subsection (a) shall be sometimes referred to herein as the “Holder Released Claims.”
Notwithstanding the foregoing, the Holder Released Claims do not include any Excepted Claims (as defined below).

 

(b)       Company
Release. In consideration of the Holder’s execution of this Agreement, and effective upon the Closing Date, the Company,
for itself and for its officers, directors, agents, employees, attorneys, business units, divisions, affiliates, direct or indirect
parent corporations, subsidiaries, predecessors in interest, administrators, agents, successors and assigns (collectively, the
“Company Releasors”), hereby remise, release and forever discharge, the Holder and its officers, directors,
agents, employees, attorneys, business units, divisions, affiliates, direct or indirect parent corporations, subsidiaries, predecessors
in interest, administrators, agents successors and assigns (collectively, the “Holder Releasees”) of and from
all Claims that each Company Releasor ever had, now has or hereafter may have against the Holder and/or the Holder Releasees based
upon any alleged conduct, action, or omission from the beginning of the world to the Closing Date arising out of, concerning or
relating, directly or indirectly, to the Purchase Agreement or to the purchase, sale, or issuance of the Shares or Warrants and
related agreements or actions. The Claims released by the Company Releasors pursuant to this Subsection (b) shall be sometimes
referred to herein as the “Company Released Claims.” Notwithstanding the foregoing, the Company Released Claims
do not include any Excepted Claims (as defined below).

 

    	 	4	 

     

    

 

(c)       Release
of Unknown Claims. Each of the parties acknowledges that it has been advised by his/its attorneys concerning, and is familiar
with, California Civil Code Section 1542 and hereby expressly waives any and all provisions, rights, and benefits conferred by
that section and by any law of any state or territory of the United States, or principle of common law, that is similar, comparable
or equivalent to the provisions of Section 1542, which reads as follows:

 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE
CREDITOR DOES NOT KNOW OF OR SUSPECT TO EXIST IN ITS FAVOR AT THE TIME OF EXECUTING THE RELEASE WHICH, IF KNOWN BY HIM/HER, MAY
HAVE MATERIALLY AFFECTED ITS SETTLEMENT WITH THE DEBTOR.”

 

Notwithstanding the provisions of Section 1542, and for the
purposes of implementing a full and complete release, discharge and hold harmless of the claims herein described, each of the parties
expressly acknowledges that this release, discharge and hold harmless is intended to include all claims, including those which
the parties do not know or suspect to exist in his/its favor at the time of his/its signature, and that this release, discharge
and hold harmless will extinguish any such claims.

 

(d)       Exceptions
to Releases. The releases set forth in this Section 7 are not intended to, and shall not, release (collectively, the
“Excepted Claims”): (i) any Claims based on, arising out of or relating to conduct, actions or omissions occurring
after the date hereof; (ii) any person or entity from any performance under or compliance with any of the terms, conditions or
other provisions of this Agreement or Articles IV or V of the Purchase Agreement, in each case after the date hereof (for clarity,
even if such terms, conditions and provisions were also in existence prior to the date hereof), or (iii) any warrant to purchase
capital stock of the Company issued by the Company to any Holder that is outstanding as of the date hereof.

 

(e)       No
Pending Actions. Each of the parties represents that, as of the date of this Agreement, it has not initiated, filed, prosecuted
or pursued any claim, complaint or charge against the Company Releasees or Holder Releasees, as applicable, with any federal, state
or local court, agency or association, or any arbitral body.

 

8.       Termination.
In the event the Closing does not occur on or before September 30, 2017, this Agreement shall terminate and be of no further force
and effect, each party shall be released from its obligations hereunder, and the releases contained in paragraph 7 will be null
and void.

 

9.       Miscellaneous.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered
by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if
such facsimile or “.pdf” signature page were an original thereof. By executing this Agreement, each of the parties
evidences that it carefully read and fully understands all of the provisions of this Agreement.  Each party further acknowledges
that, in executing this Agreement, it has not relied on any promise of future benefit or any statement of any of the parties, or
anyone representing any of the parties, whether written or oral, not set forth in this Agreement.

 

    	 	5	 

     

    

 

10.       Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached to
the Purchase Agreement at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date
of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the
email address as set forth on the signature pages attached to the Purchase Agreement on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The contact information for such notices and communications shall be as set forth on the signature pages attached
to the Purchase Agreement unless a party to this Agreement delivers updated contact information to the other party. To the extent
that any notice provided pursuant to this Agreement constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form
8-K.

 

11.       Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Agreement), and
hereby irrevocably waives, and agrees not to assert in any Action or Proceeding (each as defined in the Purchase Agreement), any
claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is
an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to
limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action or Proceeding
to enforce any provisions of this Agreement, then the prevailing party in such Action or Proceeding shall be reimbursed by the
non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such Action or Proceeding.

 

    	 	6	 

     

    

 

12.       Equal
Treatment of Participating Holders. The Company shall not amend or waive any terms to any Repurchase Agreement on terms more
favorable to a holder party to a Repurchase Agreement (each, a “Participating Holder”) (including payment of
consideration for such amendment or waiver) unless the Company ratably amends or waives such terms for all Participating Holders.
For clarification purposes, this provision constitutes a separate right granted to each Participating Holder by the Company and
negotiated separately by each Participating Holder, and is intended for the Company to treat the Participating Holders as a class
and shall not in any way be construed as the Participating Holders acting in concert or as a group with respect to the purchase,
disposition or voting of securities or otherwise. The Company hereby represents and warrants as of the date hereof and covenants
and agrees that none of the terms offered to any Person with respect to the transactions contemplated by the Repurchase Agreements,
including, without limitation with respect to any consent, release, amendment, settlement, or waiver relating to the transaction
contemplated by the Repurchase Agreements (each a “Repurchase Document”), is or will be more favorable to such
Person than those of the Holder and this Agreement. For the avoidance of doubt, the agreement by the Company to reimburse the reasonable
legal fees of Feuerstein Kulick LLP as counsel to a Participating Holder shall not be deemed to be a term more favorable to any
Person than those of the Holder and this Agreement. If, and whenever on or after the date hereof, the Company enters into a Repurchase
Document (other than a substantially identical Repurchase Agreement), then (i) the Company shall provide notice thereof to the
Holder promptly following the occurrence thereof and (ii) the terms and conditions of this Agreement shall be, without any further
action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that
the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such Repurchase
Document, provided that upon written notice to the Company at any time the Holder may elect not to accept the benefit of any such
amended or modified term or condition, in which event the term or condition contained in this Agreement shall apply to the Holder
as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with
respect to the Holder. The provisions of this Section 12 shall apply similarly and equally to each Repurchase Document.

 

13.       Securities
Law Disclosure; Confidentiality. The Company shall file a Current Report on Form 8-K or Quarterly Report on Form 10-Q disclosing
the material terms of the transactions contemplated hereby with the Commission within the time required by the Exchange Act (the
“Exchange Act Filing”). From and after the issuance of the Exchange Act Filing, the Holder shall not be in possession
of any material, nonpublic information received from the Company or any of its subsidiaries or any of their respective officers,
directors, employees, affiliates or agents, that is not disclosed in the Exchange Act Filing. The Company shall not, and shall
cause its officers, directors, employees, affiliates and agents, not to, provide the Holder with any material, nonpublic information
regarding the Company from and after the filing of the Exchange Act Filing without the express written consent of the Holder. To
the extent that the Company delivers any material, non-public information to the Holder from and after the filing of the Exchange
Act Filing without the Holder’s express prior written consent, the Company hereby covenants and agrees that the Holder shall not
have any duty of confidentiality to the Company, any of its subsidiaries or any of their respective officers, directors, employees,
affiliates or agent with respect to, or a duty to the to the Company, any of its subsidiaries or any of their respective officers,
directors, employees, affiliates or agent or not to trade on the basis of, such material, non-public information. The Company shall
not disclose the name of the Holder in any filing, announcement, release or otherwise, unless such disclosure is required by law
or regulation. In addition, effective upon the filing of the Exchange Act Filing, the Company acknowledges and agrees that any
and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries
or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Holder or any of its
affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and confirms that
the Holder will rely on the foregoing representations in effecting transactions in securities of the Company. Holder covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales,
including Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement
and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the Exchange
Act Filing. Holder covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by
the Company, Holder will maintain the confidentiality of the existence and terms of this Agreement.

 

[Signature
Pages Follow]

 

    	 	7	 

     

    

 

The undersigned have
executed this Warrant Repurchase Agreement as of the date first above written.

 

	 	THE COMPANY:	 
	 	 	 	 
	 	EKSO BIONICS HOLDINGS, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:	   	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	HOLDER:	 
	 	 	 	 
	 	Name of Holder:	 
	 	 	 	 
	 	 	 	 
	 	By:	    	 
	 	 	Name:	 
	 	 	Its:	 
	 	 	 	 
	 	Number of Shares of Common Stock subject to Common Stock Purchase Warrant held by Holder:	 
	 	 	 
	 	    	 

 

    	Signature Page to Warrant Repurchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]